Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
Lymphoma
About this trial
This is an interventional treatment trial for Lymphoma focused on measuring primary central nervous system non-Hodgkin lymphoma
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically confirmed newly diagnosed primary CNS lymphoma confirmed by 1 of the following methods: Brain biopsy or resection Cerebrospinal fluid (CSF) cytology Positive CSF cytology with or without measurable intracranial disease No evidence of systemic non-Hodgkin's lymphoma CT scan or MRI of the chest, abdomen, and pelvis AND bilateral bone marrow biopsy or unilateral biopsy with a 2cm core biopsy specimen that is negative for extracerebral source of lymphoma Measurable contrast-enhancing disease by MRI of the brain and spine (plus gadolinium) unless CSF cytology positive No evidence of pleural effusions or ascites PATIENT CHARACTERISTICS: Age Any age Performance status ECOG 0-2 Life expectancy Not specified Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Hepatic ALT and AST ≤ 2 times upper limit of normal Bilirubin ≤ 2 mg/dL Renal Creatinine clearance ≥ 50 mL/min Other Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for at least 6 months after study participation HIV negative PRIOR CONCURRENT THERAPY: Biologic therapy Not specified Chemotherapy Not specified Endocrine therapy Concurrent steroids for the management of symptoms related to lymphoma allowed Radiotherapy No concurrent palliative radiotherapy Surgery Not specified
Sites / Locations
- UCSF Helen Diller Family Comprehensive Cancer Center
- Tunnell Cancer Center at Beebe Medical Center
- CCOP - Christiana Care Health Services
- University of Chicago Cancer Research Center
- Fort Wayne Medical Oncology and Hematology
- Hematology Oncology Associates of the Quad Cities
- Menorah Medical Center
- Saint Luke's Hospital - South
- Shawnee Mission Medical Center
- Union Hospital Cancer Program at Union Hospital
- Masonic Cancer Center at University of Minnesota
- Truman Medical Center - Hospital Hill
- Saint Luke's Cancer Institute at Saint Luke's Hospital
- St. Joseph Medical Center
- North Kansas City Hospital
- Parvin Radiation Oncology
- CCOP - Kansas City
- Research Medical Center
- Saint Luke's East - Lee's Summit
- Liberty Hospital
- Heartland Regional Medical Center
- Cancer Institute of New Jersey at Cooper - Voorhees
- Stony Brook University Cancer Center
- SUNY Upstate Medical University Hospital
- Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center
- Rhode Island Hospital Comprehensive Cancer Center
- Miriam Hospital
- Mountainview Medical
- Fletcher Allen Health Care - University Health Center Campus
- Danville Regional Medical Center
Arms of the Study
Arm 1
Experimental
Intensive Combination Chemo & Immunotherapy
Induction Cycles 1-3: Methotrexate 8gm/m^2 days 1 & 15; Leucovorin 100 mg/m^2 days 2 & 16; Rituximab 375 mg/m^2 days 3, 10, 17 & 24 of cycle 1, days 3 & 10 of cycle 2; Temozolomide 150 mg/m^2/day PO days 7-11 Induction Cycle 4: Temozolomide 150 mg/m^2/day PO days 7-11; Methotrexate 8gm/m^2 day 15; Leucovorin 100 mg/m^2 day 16 Consolidation Cycle 5: Methotrexate 8gm/m^2 days 1; Leucovorin 100 mg/m^2 days 2; Temozolomide 150 mg/m^2/day PO days 7-11 Consolidation Cycle 6: Cytarabine 2 g/m^2 (x 8 doses) days 1-4; Etoposide 5 mg/kg (x 8 doses) days 1-4; G-CSF 5 mcg/kg/day or GM-CSF 250 mcg/m^2/day starting day 14 until ANC recovers (>= 500 for 2 consecutive days or >= 1500 for one day)